Spruce Biosciences, Inc. SPRB 深 沪
已收盘 02-06 16:00:00 美东时间
72.40
+1.550
+2.19%
华盛通- 最 高74.40
- 今 开71.17
- 成交量 3.00万股
- 最 低 71.00
- 昨 收 70.85
- 总市值 7749.48万
- 52周最高 240.00
- 市盈率 静 --
- 换手率 2.80%
- 52周最低 7.26
- 委 比 -1.23%
- 总股本 107.04万
- 历史最高 240.00
- 量 比 1.28
- 振 幅 4.80%
- 历史最低 7.26
- 每 手 1
- 风险率 43.10%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and developme...
01-19 08:02
Spruce Biosciences Strikes Up To $50M, 42-Month Loan Facility With Avenue Venture Opportunities Fund II
Spruce Biosciences, Inc. (Spruce) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today
01-08 21:19
美股大行评级 | 潜在涨幅63.56%！拜玛林制药获Truist Securities升目标价至100美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持拜玛林制药"买入"评级，目标价从80美元升至100美元；HC Wainwright & Co.：维持Savara"买入"评级，目标价从8美元升至10美元
2025-12-24 11:17
美股大行评级 | 潜在涨幅498.16%！SurgePays Inc获Ascendiant Capital升目标价至9.75美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持SurgePays Inc"买入"评级，目标价从9.5美元升至9.75美元；Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从8美元升至10美元
2025-12-23 12:32
HC Wainwright & Co. Assumes Spruce Biosciences at Buy, Announces Price Target of $220
HC Wainwright & Co. analyst Raghuram Selvaraju assumes Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $220.
2025-12-22 19:31
美股大行评级 | 美鹰服饰、CrowdStrike、迈威尔科技获多家机构上调目标价；ACHC、GitLab、Okta遭多家机构下调目标价
今日重点评级关注：Guggenheim：维持Cybin Inc. Common Shares"买入"评级，目标价从39美元升至48美元；HC Wainwright & Co.：维持Capricor Therapeutics"买入"评级，目标价从24美元升至60美元
2025-12-04 09:38
Leerink Partners Upgrades Spruce Biosciences to Outperform, Announces $160 Price Target
Leerink Partners analyst Joseph Schwartz upgrades Spruce Biosciences (NASDAQ:SPRB) from Market Perform to Outperform and announces $160 price target.
2025-12-03 21:44
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
2025-11-12 11:43
Citizens Maintains Market Outperform on Spruce Biosciences, Raises Price Target to $259
Citizens analyst Jonathan Wolleben maintains Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and raises the price target from $254 to $259.
2025-11-11 21:55
SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. Q3 EPS $(14.58) Misses $(13.94) Estimate
SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. (OTC:SPRB) reported quarterly losses of $(14.58) per share which missed the analyst consensus estimate of $(13.94) by 4.63 percent. This is a 7.43 percent increase over
2025-11-11 06:31
